TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of symptomatic seasonal or perennial allergic rhinitis~* Active rhinoconjunctivitis~* Six week standard treatment before inclusion~* Confirmation of an Immunoglobulin E-mediated response through previous positive skin or in vitro allergen testing~Exclusion Criteria:~* Other immunological immune-mediated diseases such as autoimmune diseases and cancer.~* Unstable chronic disease, such as diabetes, cardiac diseases, chronic kidney failure, chronic hepatic disease.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- DLE plus standard medications (Type: EXPERIMENTAL): DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18-65 yr old adults with asthma, non-smoking for at least one year~* Healthy non-smoking adults, aged 18-65 without asthma~* Heavy subjects with BMI \> 30 kg/m2~* Subjects with normal weight (BMI between 20-25 kg/m2)~* Subject not taking anti-leukotriene therapy (Singulair, Accolate, Zyflo)~Exclusion Criteria:~* No chronic oral steroid use~* No recent history of infection~* No recent history of flare of lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy non-asthmatic obese adults (Type: None): Healthy non-asthmatic obese adults
- Healthy non-asthmatic non-obese adults (Type: None): Healthy non-asthmatic non-obese adults
- Asthmatic obese adults (Type: None): Asthmatic obese adults
- Asthmatic non-obese adults (Type: None): Asthmatic non-obese adults

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or more~* Admitted to the ICU~* Already receiving or needing insulin infusion for blood glucose control~Exclusion Criteria:~* Not critically ill (eating, not mechanically ventilated)~* Pregnant or breastfeeding~* Previous inclusion into the trial~* Included in other trial~* Moribund~* Diabetes coma~* No arterial line available

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LOGIC-Insulin (Type: EXPERIMENTAL): Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
- Nurse-directed (Type: ACTIVE_COMPARATOR): Nurse-directed blood glucose control (80-110 mg/dL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bacteraemia Secondary to Tooth Extraction: Chlorhexidine Prophylaxis Protocols

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* with need for dental extraction~Exclusion Criteria:~* patients under 18 years of age~* antibiotic treatment in the previous three months~* routine use of oral antiseptics~* any type of congenital or acquired immunodeficiency or other disease that could favour the onset of infection or haemorrhagic complications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: OTHER): * Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~* No prophylactic Chlorhexidine regimen.~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction.
- CHX-Mouthwash (Type: ACTIVE_COMPARATOR): * Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction.
- CHX-MW/SUB_IR (Type: ACTIVE_COMPARATOR): * Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction.
- CHX-MW/SUPRA_IR (Type: ACTIVE_COMPARATOR): * Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~* Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.~* Local anesthesia with lidocaine plus adrenaline (1:100,000).~* Tooth extraction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age.~2. Patient completed the entire treatment period of one of the following studies: PRU-USA-3, PRU-USA-11, PRU-USA-13, PRU-USA-21, PRU-USA-25, PRU-USA-27 or PRU-USA-28, or Patient participated in the re-treatment study PRU-USA-28 and did not qualify for Treatment period II after both washout periods.~Exclusion Criteria:~1. Patient with impaired renal function~2. Patient with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.~3. Female of childbearing potential without adequate contraceptive protection during the study.~4. Patient who used an investigation drug other than prucalopride in the 30 days preceding the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Chronic Kidney Disease (CKD) Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 20 years or above at the time of informed consent~* Chronic Kidney Disease patients with Epidermal growth factor receptor (eGFR) under 60 ml/min/1.73m2 (stage 3, 4 and 5) who have not been on dialysis~* Patients who had been in the care of a physician for Chronic Kidney Disease for \>2 months and was not expected to begin dialysis for at least 4 months~* Patients with serum phosphate levels 5.6 mg/dL to 11.0 mg/dL at Week -4 (Visit 1) or Week -2 (Visit 2)~Exclusion Criteria:~* Patients with hypocalcemia or hypercalcemia (corrected serum calcium level of \< 7.0 mg/dL or \>/- 11.0 mg/dL) at Week -2 (Visit 2).~* Significant renal impairments~* Had acute renal failure within 3 months of Run-in period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of UCB and MSCs in Children With CP: ACCeNT-CP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥24 months and ≤60 months adjusted age at the time of enrollment.~2. Diagnosis: Unilateral or bilateral hypertonic cerebral palsy secondary to in utero or perinatal stroke/hemorrhage, hypoxic ischemic encephalopathy (including, but not limited to, birth asphyxia), and/or periventricular leukomalacia.~3. Performance status: Gross Motor Function Classification Score levels I - IV~4. Review of brain imaging (obtained as standard of care prior to study entry) does not suggest a genetic condition or brain malformation.~5. Legal authorized representative consent.~Exclusion Criteria:~1. Available qualified autologous cord blood unit.~2. Hypotonic or ataxic cerebral palsy without spasticity.~3. Autism and autistic spectrum disorders.~4. Hypsarrhythmia.~5. Legally blind~6. Intractable seizures causing epileptic encephalopathy.~7. Evidence of a progressive neurologic disease.~8. Has an active, uncontrolled systemic infection or documentation of HIV+ status.~9. Known genetic disease or phenotypic evidence of a genetic disease on physical exam.~10. Concurrent genetic or acquired disease or comorbidity(ies) that could require a future allogeneic stem cell transplant.~11. Requires ventilatory support, including home ventilator, CPAP, BiPAP, or supplemental oxygen.~12. Impaired renal or liver function as determined by serum creatinine \>1.5mg/dL and/or total bilirubin \>1.3mg/dL except in patients with known Gilbert's disease.~13. Possible immunosuppression, defined as WBC \<3,000 cells/mL or absolute lymphocyte count (ALC) \<1500 with abnormal T-cell subsets.~14. Patient's medical condition does not permit safe travel.~15. Previously received any form of cellular therapy.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 60 Months
- Healthy Volunteers: f

Study Arms:
- Allogeneic Umbilical Cord Blood (Type: EXPERIMENTAL): Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
- Cord Tissue Mesenchymal Stromal Cells (Type: EXPERIMENTAL): Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
- Natural History (Type: ACTIVE_COMPARATOR): Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female with iron deficiency anemia~* Hg \</= 11 g/dL~Exclusion Criteria:~* Previous participation in a FCM trial~* Known Hypersensitivity to FCM~* History of anemia other that anemia due to heavy uterine bleeding or the post partum state~* current history of GI bleeding~* Received IV Iron within the month prior~* Anticipated need for surgery~* Malignancy history~* AST or ALT greater than normal~* Received an investigational drug within 30 days of screening~* Pregnant or sexually active females who are not willing ot use an effective form of birth control

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
- Standard Medical Care (SMC) (Type: ACTIVE_COMPARATOR): Varied as determined by the Investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed multiple sclerosis~* Subjective experience of affected balance and walking~* Being able to walk 100 meters with assistance~Exclusion Criteria:~* Cognitive or language deficits that prevents using the self-rating scales~* Visual deficits that prevents training with television games~* Weight above 149 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Participants allocated as controls receive no treatment. They may be physically active as usual.
- Training with Nintendo Wii Fit (Type: EXPERIMENTAL): Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I and II women~* 18-45 yrs old~* Singleton pregnancy~* Cervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia~* Height 150 - 180 cm~* BMI ≤ 40 kg/m2.~Exclusion Criteria:~* Any contraindication to neuraxial anesthesia (history of neurologic disease (e.g., multiple sclerosis, spinal stenosis, central or peripheral neuropathy)~* Pre-existing/chronic back pain~* Ester local anesthetic allergy, PABA allergy~* History of atypical cholinesterase (CP is metabolized by cholinesterase)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chloroprocaine (CP) (Type: EXPERIMENTAL): Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
- Bupivacaine (BUP) (Type: ACTIVE_COMPARATOR): Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to \~ 2 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~- Generally healthy of at least 18 years of age with active rheumatoid arthritis.~Exclusion:~- A history or presence of clinically important medical disease.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)~Extension Studies:~* First extension: Patient completed the 48-week base study~* Second extension: Patient completed the first 144-week extension study~Exclusion Criteria:~* Less than 18 years of age~* Individuals who currently do not test positive for HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 600 mg monotherapy (Type: EXPERIMENTAL): MK0518 600 mg twice daily
- 400 mg monotherapy (Type: EXPERIMENTAL): MK0518 400 mg twice daily
- 200 mg monotherapy (Type: EXPERIMENTAL): MK0518 200 mg twice daily
- 100 mg monotherapy (Type: EXPERIMENTAL): MK0518 100 mg twice daily
- placebo monotherapy (Type: PLACEBO_COMPARATOR): Placebo to MK0518 twice daily
- 600 mg combo therapy (Type: EXPERIMENTAL): MK0518 600 mg + tenofovir + lamivudine
- 400 mg combo therapy (Type: EXPERIMENTAL): MK0518 400 mg + tenofovir + lamivudine
- 200 mg combo therapy (Type: EXPERIMENTAL): MK0518 200 mg + tenofovir + lamivudine
- 100 mg combo therapy (Type: EXPERIMENTAL): MK0518 100 mg + tenofovir + lamivudine
- EFV combo therapy (Type: ACTIVE_COMPARATOR): efavirenz + tenofovir + lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Mothers may be eligible for this study if they:~* Receive prenatal care at King Edward VIII Hospital, Durban, or St. Mary's Hospital, Marianhill, South Africa; or polyclinics in Chitungwiza District, Zimbabwe.~* Are pregnant for at least 30 weeks before giving birth.~* Are at least 18 years of age.~* Are HIV-positive by 2 ELISA tests.~* Have no serious current or previous problems in pregnancy (e.g., seizures).~* Have a fixed home and/or work address.~* Plan to deliver the baby at a hospital or clinic where the study is based.~* Plan to breast-feed their babies.~* Infants may be eligible for this study if they:~* Are born to women participating in this study.~* Weigh at least 2.5 kg at birth.~* Begin breast-feeding by 48 hours.~Exclusion Criteria~Mothers will not be eligible for this study if they:~* Have AIDS or any other serious illness.~* Are using illegal drugs or have been using alcohol for a long time.~* Are sensitive to NVP.~* Have taken any nonnucleoside reverse transcriptase inhibitors in the past.~* Are using rifampin, rifabutin, ketoconazole, macrolides, or cimetidine.~* Infants will not be eligible for this study if they:~* Have jaundice (yellowing of the skin and whites of eyes) that requires a blood transfusion.~* Have any serious or life-threatening condition(s).

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* female patients with cancer breast scheduled for modified radical mastectomy with axillary dissection~Exclusion Criteria:~* allergy to the study drugs~* significant cardiac, respiratory, renal or hepatic disease~* drug or alcohol abuse~* psychiatric illness that would interfere with perception and assessment of pain

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- local instillation of morphine 5 mg (Type: ACTIVE_COMPARATOR): 5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
- local instillation of morphine 10 mg (Type: ACTIVE_COMPARATOR): 5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
- local instillation of morphine 15 mg (Type: ACTIVE_COMPARATOR): 5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
- local instillation of local anesthetics (Type: PLACEBO_COMPARATOR): 5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete